LaMattina

Showing 5 posts of 5 posts found.

FDA image

FDA approvals: 1996 versus 2014

January 12, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, LaMattina, NDA, US, appovals, drugs

As highlighted in a number of recent stories, 2014 was a banner year for the biopharmaceutical industry with 41 new …

LaMattina image

Drug prices defy gravity – until patent expiry

June 23, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing John LaMattina, LaMattina, Pfizer, drug, pharma, pricing, research

How drugs are priced is a hot topic these days, and a new Bloomberg article will cause it to heat-up …

John LaMattina: India’s solution to drug costs

May 13, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing India, LaMattina, R&D

Drug pricing is a major issue in India. The Indian government believes that the prices of lifesaving drugs shouldn’t be …

screen_shot_2013-03-20_at_09

Ziarco appoints John LaMattina as R&D advisor

March 20, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing LaMattina, Ziarco

Ex-global head of Pfizer R&D and Pharmafocus regular John LaMattina has been given a strategic advisory role by biotech firm …

Mergers and spending cuts damaging drug research

August 3, 2011
Research and Development, Sales and Marketing LaMattina, Pfizer, research productivity

Big pharma’s policy of mergers and swingeing cuts is having a devastating effect on drug research, says a former Pfizer …

Latest content